



South Dakota  
Department of  
**Social Services**

**DEPARTMENT OF SOCIAL SERVICES**

DIVISION OF MEDICAL SERVICES  
700 GOVERNORS DRIVE  
PIERRE, SD 57501-2291  
PHONE: 605.773.3495  
FAX: 605.773.5246  
WEB: [dss.sd.gov](http://dss.sd.gov)

September 14, 2020

**ATTENTION:** Provider and Billing Professionals

**FROM:** South Dakota Medicaid

**RE:** September 2020 Updates to the COVID-19 FAQ

South Dakota Medicaid continues evaluate and add flexibilities to the Medicaid program to allow providers to address the COVID-19 Public Health Emergency (PHE) and meet the needs of Medicaid recipients. South Dakota Medicaid has added the following information about coverage and flexibilities since the last release of the Provider FAQ:

**COVID-19 Treatment**

South Dakota Medicaid covers testing for COVID-19 without cost sharing requirements.

Providers must use diagnosis code U07.1(COVID-19) on all claims submitted for treatment of COVID-19.

Providers should refer to the [ICD-10 Official Coding and Reporting Guidelines April 1, 2020 through September 30, 2020](#) released by the CDC for detailed coding information related to COVID-19.

In order to better track treatment for COVID-19, CMS has released new COVID-19 treatment inpatient hospital procedure codes, SD Medicaid will accept these codes effective August 1, 2020.

| <b>Procedure Code</b> | <b>Description</b>   |
|-----------------------|--|
| XW013F5               | Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 |
| XW033E5               | Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5                      |
| XW033F5               | Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5     |

The Department of Social Services does not exclude, deny benefits to, or otherwise discriminate against any person on the basis of actual or perceived race, color, religion, national origin, sex, age, sexual orientation or disability in admission or access to, or treatment or employment in its programs, activities, or services. For more information about this policy or to file a Discrimination Complaint you may contact: Discrimination Coordinator, Director of DSS Division of Legal Services, 700 Governor's Drive, Pierre SD 57501, 605-773-3305.

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-800-305-9673 (TTY: 711).

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1-800-305-9673 (TTY: 711).

|         |  |
|---------|--|
| XW033G5 | Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5                                |
| XW033H5 | Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5                              |
| XW043E5 | Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5                   |
| XW043F5 | Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5  |
| XW043G5 | Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5                                   |
| XW043H5 | Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5                                 |
| XW0DXF5 | Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5 |
| XW13325 | Transfusion of Convalescent Plasma (Nonautologous) into Peripheral Vein, Percutaneous Approach, New Technology Group 5       |
| XW13325 | Transfusion of Convalescent Plasma (Nonautologous) into Peripheral Vein, Percutaneous Approach, New Technology Group 5       |
| XW14325 | Transfusion of Convalescent Plasma (Nonautologous) into Central Vein, Percutaneous Approach, New Technology Group 5          |
| XW14325 | Transfusion of Convalescent Plasma (Nonautologous) into Central Vein, Percutaneous Approach, New Technology Group 5          |

A complete list of all of the coverage and flexibilities being offered by South Dakota Medicaid to address COVID-19 can be found on the [DSS COVID-19 Resources page](#) and the [Medicaid Provider FAQ](#).

### **Indian Health Services (IHS) and Tribal 638 Offsite Testing**

IHS and Tribal 638 providers are temporarily allowed to be reimbursed at the encounter rate for offsite COVID-19 testing services. CMS is temporarily allowing this flexibility until January 30, 2021. CPT code 99212 should be listed on the claim for specimen collection.

### **IHS and Tribal 638 Telemedicine Services**

IHS and Tribal 638 providers are temporarily allowed to be reimbursed at the encounter rate for telemedicine services when neither the practitioner nor the recipient are located in the clinic at the time of the service. CMS is temporarily allowing this flexibility until January 30, 2021. Telemedicine services must be provided in accordance with the [Telemedicine](#) manual.